The prevalence of lymphedema in Canada: An update.
Pathways · 2024
DOI: 10.70472/cdpu5571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathways, 2024. Verfasst von David Keast und 3 weiteren Autor:innen.
Abstract (Originalsprache)
It is vitally important to know the prevalence and impact of a condition to justify the allocation of health care resources. Chronic edema/lymphedema continues to be poorly recognized and poorly treated. Even within the lymphedema community, some basic questions still need to be answered. How do we define lymphedema? What diagnostic methods should be used? What volume differences? We have no accepted international guidance on this. In estimating prevalence, do we only include stages 2 and 3, ignoring those in earlier stages who might only have limb swelling and/or feel heaviness at the end of the day? For the purposes of the current exercise, we have only considered those with established chronic edema/ lymphedema; however, those with early signs also need preventive advice and treatment.
Zitieren
APA
Keast, D., Towers, A., Letellier, M., & Damji, A. (2024). The prevalence of lymphedema in Canada: An update. Pathways. https://doi.org/10.70472/cdpu5571
Vancouver
Keast D, Towers A, Letellier M, Damji A. The prevalence of lymphedema in Canada: An update. Pathways. 2024. doi:10.70472/cdpu5571
BibTeX
@article{Keast2024,
author = {Keast, David and Towers, Anna and Letellier, Marie-Eve and Damji, Alisha},
title = {The prevalence of lymphedema in Canada: An update},
journal = {Pathways},
year = {2024},
doi = {10.70472/cdpu5571}
}
EUVIMED